Cover Image
市場調查報告書

Synageva BioPharma Corp.的產品平台分析

Synageva BioPharma Corp. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 192839
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
Synageva BioPharma Corp.的產品平台分析 Synageva BioPharma Corp. - Product Pipeline Review - 2014
出版日期: 2014年06月15日 內容資訊: 英文 35 Pages
簡介

Synageva BioPharma Corp.ha是從事針對罕見疾病用醫藥品的藥物研究、開發,銷售的生物醫藥品企業。

本報告提供Synageva BioPharma Corp.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Synageva BioPharma Corp.的基本資料

Synageva BioPharma Corp.概要

  • 主要資訊
  • 企業資料

Synageva BioPharma Corp.:R&D概要

  • 主要的治療範圍

Synageva BioPharma Corp.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Synageva BioPharma Corp.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Synageva BioPharma Corp.:藥物簡介

  • sebelipase alfa
  • Multiple New Programs
  • SBC-103
  • SBC-104
  • SBC-105
  • SBC-106
  • SBC-204
  • SBC-238

Synageva BioPharma Corp.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型

Synageva BioPharma Corp.:最近的開發平台趨勢

Synageva BioPharma Corp.:暫停中的計劃

Synageva BioPharma Corp.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • TRI-999

Synageva BioPharma Corp.:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04994CDB

Global Markets Direct's, 'Synageva BioPharma Corp. - Product Pipeline Review - 2014', provides an overview of the Synageva BioPharma Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Synageva BioPharma Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Synageva BioPharma Corp. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Synageva BioPharma Corp.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Synageva BioPharma Corp.'s pipeline products

Reasons to buy

  • Evaluate Synageva BioPharma Corp.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Synageva BioPharma Corp. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Synageva BioPharma Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Synageva BioPharma Corp. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Synageva BioPharma Corp.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Synageva BioPharma Corp. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Synageva BioPharma Corp. Snapshot
    • Synageva BioPharma Corp. Overview
    • Key Information
    • Key Facts
  • Synageva BioPharma Corp. - Research and Development Overview
    • Key Therapeutic Areas
  • Synageva BioPharma Corp. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Synageva BioPharma Corp. - Pipeline Products Glance
    • Synageva BioPharma Corp. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Synageva BioPharma Corp. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Synageva BioPharma Corp. - Drug Profiles
    • sebelipase alfa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Multiple New Programs
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SBC-103
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SBC-104
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SBC-105
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SBC-106
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SBC-204
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SBC-238
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Synageva BioPharma Corp. - Pipeline Analysis
    • Synageva BioPharma Corp. - Pipeline Products by Target
    • Synageva BioPharma Corp. - Pipeline Products by Route of Administration
    • Synageva BioPharma Corp. - Pipeline Products by Molecule Type
  • Synageva BioPharma Corp. - Recent Pipeline Updates
  • Synageva BioPharma Corp. - Dormant Projects
  • Synageva BioPharma Corp. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
    • TRI-999
  • Synageva BioPharma Corp. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Synageva BioPharma Corp., Key Information
  • Synageva BioPharma Corp., Key Facts
  • Synageva BioPharma Corp. - Pipeline by Indication, 2014
  • Synageva BioPharma Corp. - Pipeline by Stage of Development, 2014
  • Synageva BioPharma Corp. - Monotherapy Products in Pipeline, 2014
  • Synageva BioPharma Corp. - Phase III, 2014
  • Synageva BioPharma Corp. - Preclinical, 2014
  • Synageva BioPharma Corp. - Pipeline by Target, 2014
  • Synageva BioPharma Corp. - Pipeline by Route of Administration, 2014
  • Synageva BioPharma Corp. - Pipeline by Molecule Type, 2014
  • Synageva BioPharma Corp. - Recent Pipeline Updates, 2014
  • Synageva BioPharma Corp. - Dormant Developmental Projects,2014
  • Synageva BioPharma Corp. - Discontinued Pipeline Products, 2014
  • Synageva BioPharma Corp., Subsidiaries

List of Figures

  • Synageva BioPharma Corp. - Pipeline by Top 10 Indication, 2014
  • Synageva BioPharma Corp. - Pipeline by Stage of Development, 2014
  • Synageva BioPharma Corp. - Monotherapy Products in Pipeline, 2014
  • Synageva BioPharma Corp. - Pipeline by Top 10 Target, 2014
  • Synageva BioPharma Corp. - Pipeline by Top 10 Molecule Type, 2014
Back to Top